India's Supreme Court has ruled against Big Pharma and for the country's generic drug companies. But who's the big winner in the end?
When the Swiss pharmaceutical firm Novartis lost its battle in India's highest court on Monday, April 1, it was hailed as a major victory in India. The Indian Supreme Court rejected a plea by Novartis for patent protection for the drug Gleevec, which has been called a "miracle drug" for patients with some forms of leukemia. Now, Indian companies are free to make and distribute low-cost versions of the drug to the 300,000-some Indian patients currently using Gleevec. "It is a very happy day for us. Now we can cater to all cancer patients," said Kiran Hukku of Cancer Patients Aid Association, which led the case against Novartis.
When the Swiss pharmaceutical firm Novartis lost its battle in India’s highest court on Monday, April 1, it was hailed as a major victory in India. The Indian Supreme Court rejected a plea by Novartis for patent protection for the drug Gleevec, which has been called a "miracle drug" for patients with some forms of leukemia. Now, Indian companies are free to make and distribute low-cost versions of the drug to the 300,000-some Indian patients currently using Gleevec. "It is a very happy day for us. Now we can cater to all cancer patients," said Kiran Hukku of Cancer Patients Aid Association, which led the case against Novartis.
But Monday’s verdict is about much more than leukemia patients in India. It’s about India’s ability to legally continue to uphold its reputation as "the pharmacy to the third world." Over the last decade, Indian pharmaceutical companies have pioneered the method of making cheap drugs by copy-catting brand-name medications when they go out of patent for everything from HIV to malaria. These drugs are used widely in India, where tens of millions of people still live on less than two dollars a day and cannot afford basic health care costs. It’s estimated that less than 10 percent of drugs sold in India are under patent. That number can be partly accounted for by the country’s thriving business in counterfeit drugs, which makes up between 8 and 25 percent of India’s drug market. But Indian drug makers also export about $10 billion worth of generic medicine every year. That means tens of millions of people across the developing world have come to rely on India’s cheap drugs.
Essentially, the battle between Indian and multinational pharmaceutical companies boils down to a fundamental disagreement about the definition and the ethics of innovation. India’s pharmaceutical companies have a very different business model than that of the research-focused big international pharma companies. Firms like Switzerland’s Novartis and America’s Pfizer — which is the world’s largest pharmaceutical company — often spend decades and billions of dollars developing a single medication. They say they need patent protection on their drugs in order to support the high research costs that come with innovation. Indian companies do not invest in research and development on the same scale. Rather, they wait until successful drugs come off patent, and then make copycat versions to sell at a fraction of the cost across the developing world. Indian generic manufacturers sell their version of Gleevec for about $175 a month; the brand-name medication costs patients in India $1,900 a month, although Novartis has a support program that has provided over $1.7 billion worth of Gleevec, free of cost, to Indian patients since 2002.
To U.S. pharma companies, the divide seems stark: Indian companies are simply stealing and repackaging their intellectual property. Yet the view is not the same in India. There, they take the moral high ground, arguing that the long-term costs of drug production become irrelevant if they are not an option for millions of patients in the developing world. After the Novartis decision, an editorial in the Indian newspaper The Hindu declared, "The decision affirms the idea that a patent regime loses its social relevance when a drug is priced beyond the reach of the vast majority of a country’s people." Popular sentiment against U.S. and multinational pharma companies, and support for domestic generic companies, remains strong.
Take Cipla, the country’s most successful generics company. In 2001, Cipla made world headlines by offering to sell a generic version of a triple cocktail of antiretroviral drugs to HIV-positive patients in developing countries for $350 a year, per patient. The cost was radically lower: in the West, the cocktail cost between $10,000 and $15,000 a year, per patient. Today, some 40 percent of HIV/AIDS patients undergoing antiretroviral therapy worldwide take Cipla drugs. Cipla became known as the pharma company that cares. Its chairman and managing director, Yusuf Hamied, has been portrayed as a kind of Indian Robin Hood. In fact, he became a source of national pride in India. Hamied was awarded the Indian government’s highest honor, the Padma Bhushan in 2005. In an interview with Forbes Asia, Hamied claimed that he has done more humanitarian work than Bill Gates and Warren Buffet.
Last year, Cipla announced that it was slashing the prices on its cancer drugs by 75 percent, to make them not only affordable in India, but across sub-Saharan Africa and in other low-income regions. "We had taken the lead to provide affordable medicine for AIDS, and I think the time has now come — 10 years later — when we do a similar thing for cancer," Hamied told the Wall Street Journal. Not incidentally, Hamied is also one of the richest men in India. Last year, Forbes magazine declared that the ten richest tycoons who made their fortunes through generic drug manufacturing were worth a combined total of $25.7 billion. "India’s Pharma Kings," the magazine dubbed them. Generic drugs may mean terrible business for multinational pharmaceutical companies, but clearly they have been a boon to India.
The sub-continent has been a frustrating market for big pharma. When India joined the World Trade Organization in 1995, the country was required to begin offering process patents on chemical compounds. However, it wasn’t for another decade that India amended its patent protection act to recognize actual pharmaceutical products. When it did, pharmaceutical firms like Pfizer and Novartis streamed in. They had high hopes: India’s economy was growing at 6 percent a year, and it was an essentially untapped healthcare market of 1.2 billion people.
But when India amended its patent law, it also added a provision that does not protect new forms of a known substance unless it results in "increased efficacy." This clause was intended to prevent the "evergreening" of drugs, the process of prolonging the life of a patent by making incremental or minor changes, such as changing the dosage or subtly altering the formula. India also sets a higher bar for patent approval than do many countries. In the Novartis case, advocates for low-cost medications argued that the company had not made fundamental changes to Gleevec. And on Monday, India’s Supreme Court agreed, ruling that Novartis’s Gleevec had failed "in both the tests of invention and patentability."
For multinational pharmaceutical companies, Monday’s ruling was a major blow. Both Pfizer and the German multinational Bayer are already appealing decisions in Indian courts which have rule
d that generic drug manufacturers can begin making their cancer drugs. Even if they lose these cases, though, neither company is likely to pull out of India altogether. Last year, Pfizer India saw revenues of $185 million.
Here in the United States, the industry group Pharmaceutical Research and Manufacturers of America called the decision "yet another example of the deteriorating innovation environment in India." The Global Intellectual Property Center (GIPC) at the U.S. Chamber of Commerce, echoed that overall criticism: "Unfortunately, this high court decision is a symptom of a much larger problem in inadequate protection of intellectual property rights in India." GPIC also noted that its recently released study comparing IP environments across the globe had found that that India "consistently ranked last among nearly every indicator."
India has disappointed big pharma companies on every front. Not only is its economy undergoing a dramatic slowdown, but the country’s intellectual property and regulatory environment is not conducive to business, they claim — and its crop of fast-growing, successful generics companies means increased competition on all fronts. Because lobbying is illegal in India and pharmaceutical companies can only do so much, the U.S. government has taken up a position as lead advocate for improving India’s intellectual property environment. For the most part, it does so in an informal way, as with most issues. On Tuesday, the U.S. Trade Representative’s office said it was reviewing the Supreme Court’s order on Novartis.
After Monday’s ruling against Novartis, the company suggested that it may begin to pull out of research and development in India. But that’s unlikely. The possibility of great growth still beckons. According to the consulting firm PricewaterhouseCoopers, the country’s pharmaceutical sector is expected to grow to at least $50 billion in sales by 2020, from close to $19 billion in 2009. But that same report acknowledges that Indian generics companies are capable of taking a chunk of that wealth. Something like $70 billion worth of drugs will go off patent in the United States over the next three years, the report says, and India will be well-positioned to take a substantial share of the resulting new generics markets. Which means we’re likely to see a lot more frustrated multinational pharmaceutical companies pounding at the doors of the Indian justice system in years to come.
More from Foreign Policy
At Long Last, the Foreign Service Gets the Netflix Treatment
Keri Russell gets Drexel furniture but no Senate confirmation hearing.
How Macron Is Blocking EU Strategy on Russia and China
As a strategic consensus emerges in Europe, France is in the way.
What the Bush-Obama China Memos Reveal
Newly declassified documents contain important lessons for U.S. China policy.
Russia’s Boom Business Goes Bust
Moscow’s arms exports have fallen to levels not seen since the Soviet Union’s collapse.